191228-76-9

Basic information

• Product Name: 4-(4-iodophenoxy)butanoic acid ethyl ester
• Synonyms: 4-(4-iodophenoxy)butanoic acid ethyl ester
• CAS NO: 191228-76-9
• Molecular Weight: 334.154
• Mol File: 191228-76-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-(4-iodophenoxy)butanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-iodophenoxy)butanoic acid ethyl ester(191228-76-9)
• EPA Substance Registry System: 4-(4-iodophenoxy)butanoic acid ethyl ester(191228-76-9)

Safety Data

• Hazardous Substances Data: 191228-76-9(Hazardous Substances Data)

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 540-38-5 p-Iodophenol 

Downstream Products

• 1023744-14-0 ethyl 4-(4-trimethylsilylethynylphenoxy)butyrate 
• 1357504-62-1 4-(4-{4-[4-(3-ethoxycarbonylpropoxy)phenyl]-(E)-but-1-en-3-ynyl}phenoxy)butyric acid ethyl ester 
• 1151683-54-3 ethyl 4-(4-ethynylphenoxy)butanoate 
• 1269831-61-9 C₆₀H₅₇O₁₀P 
• 1269831-60-8 C₆₀H₅₇O₉PSe 
• 731847-94-2 4-(4-iodophenoxy)butanoic acid 

Relevant articles and documents

Cyclodextrin-Based [c2]Daisy Chain Rotaxane Insulating Two Diarylacetylene Cores

A [c2]daisy chain rotaxane with two diarylacetylene cores was efficiently synthesized in 53 % yield by capping a C2-symmetric pseudo[2]rotaxane composed of two diarylacetylene-substituted permethylated α-cyclodextrins (PM α-CDs) with aniline stoppers. The maximum absorption wavelength of the [c2]daisy chain rotaxane remained almost unchanged in various solvents, unlike that of the stoppered monomer, indicating that the two independent diarylacetylene cores were insulated from the external environment by the PM α-CDs. Furthermore, the [c2]daisy chain rotaxane exhibited fluorescence emission derived from both diarylacetylene monomers and the excimer, which implies that the [c2]daisy chain structure can undergo contraction and extension. This is the first demonstration of a system in which excimer formation between two π-conjugated molecules within an isolated space can be controlled by the unique motion of a [c2]daisy chain rotaxane.

PROTEIN KINASE C AGONISTS

The present disclosure relates generally to certain diacylglycerol lactone compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by protein kinase C (PKC) agonists, such as HIV.

HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS

A compound having the following formula (I): wherein R?1? is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R?2? is hydroxyamino, R?3? is hydrogen or a suitable substituent, L?1? is -(CH?2#191)?n#191- (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and L?2? is lower alkenylene, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.